Approved Abroad, Unavailable at Home: What American Patients Can Do When Europe and Japan Have the Medicine They Need

Every year, dozens of innovative therapies complete regulatory review in the European Union or Japan before the United States Food and Drug Administration has finished its own evaluation. For a patient with a progressive neurological disease, a rare cancer, or a treatment-resistant autoimmune condition, watching a potentially life-altering drug remain out of reach — despite being prescribed freely in Berlin, Tokyo, or London — can feel both maddening and deeply unfair.

The phenomenon has a name in policy circles: the FDA approval lag. And while the agency's rigorous standards exist for sound scientific and public-safety reasons, the real-world consequences for American patients deserve a thorough, honest examination.

Why the Timeline Diverges

The FDA, the European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) all evaluate the same core data — clinical trial results demonstrating safety and efficacy. Yet their procedural timelines, staffing structures, and review philosophies differ in meaningful ways.

The EMA, for instance, operates a centralized review system that allows parallel scientific assessment across member states, frequently compressing its standard review to roughly 210 active review days. Japan's PMDA has invested heavily in accelerated pathways since the early 2010s, partly in response to what Japanese patient advocates called the "drug lag" problem — a term that American advocates are now borrowing.

The FDA's standard review window is twelve months, with a six-month priority review available for therapies addressing serious conditions. On paper, these timelines appear comparable. In practice, the clock does not start until a pharmaceutical company submits a complete New Drug Application — and companies do not always submit simultaneously in every market. A manufacturer may choose to seek EMA approval first, gather post-marketing safety data from European populations, and only then approach the FDA. The result: American patients wait not just for regulatory review but for a corporate filing decision made in a boardroom, not a laboratory.

According to research published in peer-reviewed pharmacoeconomic journals, the median lag between EMA approval and FDA approval for oncology drugs approved in both jurisdictions has historically ranged from several months to more than two years, depending on the therapeutic category and the decade studied.

The Human Cost Behind the Statistics

Patient advocacy organizations have documented the consequences with painful clarity. Consider the landscape of rare diseases, where a small global patient population means a drug may reach European patients first simply because the EMA's orphan medicine incentives differ from the FDA's structure. A child in France may begin a therapy for a rare metabolic disorder while a child in Ohio with an identical diagnosis remains on older, less effective treatment.

Oncology presents similarly stark examples. Several targeted therapies for specific lung cancer mutations — identified by genetic biomarker testing — received EMA approval and entered clinical use in Europe before FDA clearance. For patients whose tumors carried those mutations, the wait was not abstract. Tumor progression does not pause for regulatory calendars.

"The system was designed to protect patients," one patient advocate noted in a recent congressional briefing on drug access reform. "But when protection becomes prolonged exclusion, we have to ask who is actually being served."

Legitimate Pathways for American Patients Who Cannot Wait

The good news is that the regulatory landscape is not a wall — it is a set of doors, some narrow and some surprisingly accessible. American patients and their physicians have several legitimate options worth understanding.

The FDA Expanded Access Program

Commonly called "compassionate use," the FDA's Expanded Access Program allows individual patients or small groups to access investigational drugs — including those already approved elsewhere — outside of a clinical trial. Physicians must submit a request to the FDA, and the manufacturer must agree to provide the drug. Approval rates for individual patient requests have historically been high, often exceeding ninety percent, though the process requires physician engagement and can involve significant paperwork.

For drugs approved in Europe or Japan but not yet in the United States, expanded access represents the most direct domestic pathway. Patients should ask their treating physician whether a specific drug qualifies and whether the manufacturer participates in compassionate use arrangements.

Clinical Trial Enrollment

If a drug is in active FDA review, it almost certainly passed through or is currently in Phase III trials. ClinicalTrials.gov — the federal government's publicly searchable database — lists every registered trial by condition, drug name, and geographic location. Enrollment in a late-stage trial provides access to the investigational therapy under medical supervision, with no out-of-pocket drug cost in most cases. For patients near major academic medical centers, this is frequently the most practical option.

The Right to Try Act

Passed in 2018, the federal Right to Try Act expanded access to experimental treatments for terminally ill patients who have exhausted approved options. Crucially, the law does not require FDA authorization for individual patient access requests — it creates a direct agreement between the patient, the physician, and the manufacturer. The law's scope is narrower than expanded access in some respects, but it removes one bureaucratic layer for qualifying patients.

International Telemedicine and Global Health Platforms

A growing number of internationally licensed telemedicine platforms connect American patients with physicians practicing in jurisdictions where a desired medication is already approved. While importing prescription drugs for personal use occupies a legally complex space under FDA policy, the agency has historically exercised enforcement discretion for small quantities of medication intended for personal use when no approved domestic equivalent exists. Patients considering this route should consult a healthcare attorney and work only with licensed, verifiable international providers. Health Pharmacy Worlds provides educational resources on navigating international pharmaceutical databases to help patients research what is available globally before initiating any conversation with their medical team.

What Regulatory Reform Could Look Like

Policy experts have proposed several structural changes to narrow the approval gap. Mutual recognition agreements — in which the FDA would give significant weight to EMA or PMDA approval decisions — have been discussed for years but have yet to materialize in a comprehensive form. The FDA's Project Orbis, launched in 2019, represents a step toward simultaneous international review for oncology drugs, coordinating submissions across multiple regulatory agencies. Early results have been encouraging, with several cancer therapies receiving coordinated approvals across the US, Canada, Australia, and other participating nations.

Congressional attention to the issue has increased, with bipartisan interest in streamlining review timelines without compromising safety standards. Patient advocacy groups continue to push for mandatory FDA response timelines when a drug has already been approved by a peer regulatory agency with comparable scientific standards.

A Global Perspective on a Domestic Problem

The FDA approval lag is, at its core, a global health equity issue expressed in domestic terms. The same molecule, the same clinical evidence, the same manufacturing standards — yet access determined by geography and regulatory timing rather than medical need.

American patients navigating this reality benefit from treating themselves as informed global health consumers. Understanding what has been approved by the EMA or PMDA, what clinical trials are enrolling domestically, and what formal access programs exist transforms a frustrating situation into an actionable one. The world's pharmaceutical knowledge does not stop at the nation's borders, and neither should a patient's search for effective care.

This article is intended for informational purposes only and does not constitute medical or legal advice. Patients should consult qualified healthcare providers before making any treatment decisions.